BIIB vs CTS · P/E 21, rev $9.89B vs P/E 22, rev $541.3M
Biogen Inc (BIIB) versus CTS Corporation (CTS) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ.
CTS Corporation (CTS) is a electronic components company listed on US.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported CTS revenue for 2025-12-31 was $541.3M. Net income was $65.3M. Revenue was up 5.0% from 2024-12-31 to 2025-12-31. CTS currently screens at market cap $1.30B and trailing P/E 22.1.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. CTS currently screens at market cap $1.30B and trailing P/E 22.1.
Not investment advice. Open the BIIB and CTS stock pages for the full models.
Not investment advice.